Pharming Group's Q3 2025 Financial Results Announcement
Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is set to release its preliminary financial results for the third quarter of 2025. This announcement will take place on November 6, 2025, when the company will also provide a comprehensive business update.
Conference Call Details
On the same day as the report, Pharming plans to host a conference call and webcast for both analysts and investors. The event is scheduled for 13:30 CET/07:30 am ET, creating an opportunity for stakeholders to gain valuable insights directly from management.
How to Join the Conference Call
Interested participants must register in advance for the conference call. Upon registration, details including dial-in information and a unique PIN will be provided, ensuring secure access to the call. It’s important to note that the company will address questions exclusively from dial-in attendees during this session.
Webcast Information
Those unable to attend the call can still tune in via the live webcast. Registration is required, and it allows users to access the broadcast seamlessly. Additionally, the webcast will be available for replay shortly after the event on the Pharming website, offering convenience for those who wish to catch up.
About Pharming Group
Pharming Group N.V. is committed to enhancing the lives of patients facing rare, severe, and life-threatening conditions. The company is advancing a robust portfolio of innovative treatments that include both small molecular treatments and biologics. Being headquartered in Leiden, the Netherlands, Pharming employs a substantial number of professionals in the United States as well.
Pharming's Mission and Vision
The vision of Pharming is built around transforming medical care for patients with unmet needs. By engaging in extensive research and development, the company aims to introduce groundbreaking therapies that can change the treatment landscape for numerous conditions.
Company's Ongoing Projects
Currently, Pharming is working on various projects and collaborations that further emphasize its commitment to advancing biopharmaceutical solutions. With continuous investment in research and strategic partnerships, the company is poised for meaningful advancements in patient health outcomes.
Contact Information for Investors
For inquiries or more information, stakeholders may reach out to Michael Levitan, the VP of Investor Relations and Corporate Communications at Pharming Group. He can be contacted via phone or email, providing a direct line for any investor-related questions.
Frequently Asked Questions
What are Pharming’s upcoming financial results announcement dates?
Pharming Group will announce its financial results for Q3 2025 on November 6, 2025.
How can I participate in the conference call?
To participate, please register for the conference call in advance to receive dial-in information and a unique PIN for accessing the call.
Where can I find the webcast after the event?
The webcast will be accessible on Pharming's official website and will also be available for replay after the live session.
What is the focus of Pharming Group as a biopharmaceutical company?
Pharming focuses on developing innovative treatments for patients suffering from rare and life-threatening diseases, aiming to transform their health outcomes.
Who can be contacted for investor inquiries at Pharming?
Investors can contact Michael Levitan, VP Investor Relations, for any inquiries regarding the company’s financials or business strategies.